Personalized Peptide-Based Vaccination against Acinetobacter baumannii
Legal Citation
Summary of the Inventive Concept
A next-generation vaccination system that leverages genotyping, peptide-based vaccines, and nanoparticle delivery to provide personalized protection against Acinetobacter baumannii
Background and Problem Solved
The original patent disclosed novel proteins and polynucleotides derived from Acinetobacter baumannii, but its limitation lies in the lack of personalization and adaptability to individual immune responses. The new inventive concept addresses this limitation by introducing a system that can identify an individual's specific immune response profile and tailor a vaccine formulation accordingly
Detailed Description of the Inventive Concept
The inventive concept comprises a microarray-based genotyping platform that analyzes an individual's genetic variability to identify their specific immune response profile. This information is then used to formulate a peptide-based vaccine tailored to the individual's profile. The vaccine is delivered via a nanoparticle-based system that targets specific immune cells, enhancing the immune response. The system also includes a diagnostic kit for rapid detection of Acinetobacter baumannii infections
Novelty and Inventive Step
The new inventive concept introduces a paradigm shift in vaccination by incorporating genotyping, personalized peptide-based vaccines, and nanoparticle delivery. This combination of technologies is new and non-obvious compared to the original patent, which focused on pharmaceutical compositions and adjuvants
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different genotyping platforms, such as next-generation sequencing, or the incorporation of additional adjuvants to enhance the immune response. Variations could also include the development of vaccines tailored to specific HLA types or immune response profiles
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the vaccine industry, particularly in the context of personalized medicine. Target markets could include hospitals, clinics, and research institutions, as well as pharmaceutical companies and biotech firms
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/104 |
| C | C07 | C07K14/212 |
| A | A61 | A61K2039/543 |
| A | A61 | A61K2039/55505 |
| A | A61 | A61K2039/55566 |
| G | G01 | G01N2333/22 |
| G | G01 | G01N2469/20 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and immunology, specifically vaccine development, peptide engineering, and diagnostic technologies for bacterial infections, with expertise in genetic analysis, antigen design, and targeted drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in molecular biology or bioengineering, familiar with vaccine development techniques, genetic sequencing, immunological profiling, and nanoparticle-based drug delivery technologies
Obviousness Rationale
A PHOSITA would recognize that the personalized vaccination approach naturally extends the foundational peptide-based vaccine concepts from the source patent by incorporating known techniques in genetic profiling and targeted delivery. The combination of genotyping, peptide selection, and nanoparticle delivery represents predictable variations that would be obvious to a skilled practitioner seeking to improve vaccine efficacy and personalization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,615 |
|---|---|
| Title | Peptides derived from Acinetobacter baumannii and their use in vaccination |
| Assignee(s) | Evaxion Biotech A/S |